Two immuno-PET clinical studies using new generation AES reagents and 68Ga started in 2012 in France, with the aim to demonstrate the feasibility of the method in CEA-positive MTC and breast carcinoma patients and to optimize the pretargeting parameters. The gene discussed is CEACAM5; the disease is medullary thyroid gland carcinoma.